5707 N. 22nd Street
Tampa, FL 33610
P:813.272.2244
F:813.272.3766

Make Donation

Medical Disorders
Resources
Basic InformationLookupsLatest News
Most Ulcerative Colitis Patients Do Not Achieve Target RemissionOral Contraceptive Use Linked to Lower Rheumatoid Arthritis RiskKidney Disease May Boost Odds of InfectionZika May Not Last in Semen as Long as ThoughtVirtual House Calls for Speedy, Effective Parkinson's CareNearly 4 Million Worldwide Die Each Year From Asthma, COPDPowerful New Cholesterol Med Won't Harm Memory, Easing ConcernsDiverse Spectrum of Neurologic Syndromes Seen With ZikaExposure to Particulate Matter Linked to Metabolic AlterationsAir Purifiers May Help the Smog-Stressed Heart'Fat But Fit' a Myth?Statin Use Among Nursing Home Residents Varies SignificantlyZika Virus Tied to Neurological Woes in AdultsAn Expert's Guide to Preventing Food PoisoningHeart Risk Up if Hospitalized for Pneumonia or SepsisSinging May Be Good Medicine for Parkinson's PatientsCPAP Doesn't Alter Renal Function in Coexisting OSA, CVDWhen Stress Hormone Falters, Your Health May SufferKidney Disease May Boost Risk of Abnormal HeartbeatCertain Jobs Linked to Raised Risk of Rheumatoid ArthritisMidlife Vascular Risk Factors Tied to Increased Risk of DementiaHigher Risk of CVD Persists After Hospital Stay for Severe InfectionAntibiotic Doesn't Prevent Lung Complication After Stem Cell TransplantHealth Tip: One of Three Adults Gets ShinglesBlood Pressure Fluctuations Tied to Dementia Risk in StudyDecline in Kids' Ear Infections Linked to Pneumococcal VaccineFDA Approves Mavyret for Hepatitis CDoes Less Sleep Make You Less Healthy?Diabetes Drug Shows Promise Against Parkinson'sReview Suggests Benefits of Aerobic Exercise in FibromyalgiaNovel Procedure Improves Kidney Transplant SuccessABP 501, Adalimumab Biosimilar, Safe and Effective, for PsoriasisSimilar Defects ID'd for T2DM, Chronic Pancreatitis and DiabetesScientists Gain Insight Into AllergiesHealth Tip: Cooling a Heat RashKnow the Signs of ConcussionDo Your Pearly Whites Sometimes Cause You Pain?Rates of Inflammatory Bowel Disease Down in Rural AreasZika Probably Not Spread Through Saliva: StudyDrug for Kidney Disease Tied to Infection RiskGum Disease May Be Linked to Cancer Risk in Older WomenStent Surgery Could Benefit Select Glaucoma PatientsBlood Proteins Linked to Severity of Chronic Fatigue SyndromeDrowning Can Occur Hours After SwimmingClimate Change May Trigger 60,000 More Premature Deaths by 2030Health Tip: Worried About Lung Disease?Thyroid Cancer Tied to Regular Thyroxine Use in HypothyroidismGene Expression May Predict Response to Methotrexate in RAHealth Tip: Get the Facts About SalmonellaRush Hour Pollution May Be Worse Than Thought
Links
Related Topics

FDA Approves Device to Help Curb Cluster Headaches

HealthDay News
by -- Robert Preidt
Updated: Apr 19th 2017

new article illustration

WEDNESDAY, April 19, 2017 (HealthDay News) -- Cluster headaches, though rare, are among the most severe forms of headache a person can face.

But there's new hope for at least some patients. The U.S. Food and Drug Administration said it has approved a hand-held device to treat these attacks.

The noninvasive device, called gammaCore, works to reduce cluster headache pain by transmitting mild electrical stimulation to the vagus nerve through the skin on the neck. This is a large nerve that runs from the brain to the colon.

One headache specialist said effective therapies are needed.

Cluster headaches "can be devastating to a person," said Dr. Noah Rosen.

"Although they are uncommon, affecting about 1 in 2,000, they are severe, disabling and poorly understood," said Rosen, who directs Northwell Health's Headache Center in Great Neck, N.Y.

While certain medications such as sumatriptan (Imitrex) are used to quell headaches, they don't always work for cluster headaches.

"Attacks that occur six or more times a day can't effectively be treated with sumatriptan safely, given the maximum daily dosage," Rosen noted.

The newly approved device might offer an alternative for at least some patients with cluster headache, however.

The gammaCore technology is made by the U.S.-based neuroscience and technology company electroCore. FDA approval of gammaCore was based on two clinical trials that found the device was more effective than placebo in reducing cluster headache pain.

One trial of 85 patients with episodic cluster headache found that it reduced pain in about a third of patients compared to about 10 percent of those on placebo.

A second trial of 27 patients found that "a significantly higher percentage of attacks were pain-free" for people using the device compared to those on placebo -- meaning that their pain had ceased by 15 minutes after headache.

According to a company news release, "gammaCore was found to be safe and well-tolerated," with most side effects being "mild and transient."

There were some caveats, however. The device should not be used by patients with an active implantable medical device, such as a pacemaker, hearing aid implant or any implanted electronic device; those diagnosed with narrowing of the arteries; those who have had surgery to cut the vagus nerve in the neck; people with clinically significant high or low blood pressure or certain irregular heart rhythms; and children or pregnant women.

It should also not be used by patients with a metallic device such as a stent, bone plate or bone screw implanted in or near the neck, or patients who are using another medical device at the same time or any portable electronic device (for example, a mobile phone).

For some cluster headache patients, gammaCore "offers a hope for a different treatment approach," Rosen said, and "may be another option for this needful community."

Dr. Sami Saba is a neurologist at Lenox Hill Hospital in New York City.

He explained that cluster headaches are thought to arise because of an abnormality in the body's autonomic nervous system. GammaCore may work because it stimulates the vagus nerve, which "also modulates the autonomic nervous system," Saba explained.

In that sense, it may be treating the origins of the painful headaches, "as opposed to merely treating the symptoms," he said.

Still, Saba pointed out that the device did not help the majority of the participants in the two studies.

GammaCore is currently available in Europe and some other parts of the world, and is expected to be available in the United States later this year, according to the news release.

More information

The Migraine Trust has more on cluster headache.